Induction of cytomegalovirus-specific T cell responses in healthy volunteers and allogeneic stem cell recipients using vaccination with messenger RNA-transfected dendritic cells

Transplantation

Volumn 99, Issue 1, 2015, Pages 120-127

  Van Craenenbroeck, Amaryllis H ^a,b   Smits, Evelien L J ^a,b   Anguille, Sébastien ^a,b   Van De Velde, Ann ^a   Stein, Barbara ^a   Braeckman, Tessa ^b   Van Camp, Kirsten ^b   Nijs, Griet ^a   Ieven, Margareta ^a   Goossens, Herman ^a   Berneman, Zwi N ^a,b   Van Tendeloo, Viggo F I ^b   Verpooten, Gert A ^a,b   Van Damme, Pierre ^b   Cools, Nathalie ^b  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^b UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CD83 ANTIGEN; CD86 ANTIGEN; CHEMOKINE RECEPTOR CCR7; CYTOMEGALOVIRUS ANTIGEN PP65; CYTOMEGALOVIRUS VACCINE; DENDRITIC CELL VACCINE; HLA DR ANTIGEN; MESSENGER RNA; CYTOMEGALOVIRUS MATRIX PROTEIN 65KDA; MATRIX PROTEIN; PHOSPHOPROTEIN; VIRUS RNA;

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CASE REPORT; CELL VIABILITY; CELLULAR IMMUNITY; CRYOPRESERVATION; CYTOMEGALOVIRUS INFECTION; DENDRITIC CELL; DRUG EFFICACY; DRUG SAFETY; ENZYME LINKED IMMUNOSPOT ASSAY; FEASIBILITY STUDY; FEMALE; GRAFT VERSUS HOST REACTION; HEADACHE; HUMAN; HUMAN CYTOMEGALOVIRUS; IMMUNOGENICITY; INFECTION CONTROL; INJECTION SITE SWELLING; LEUKAPHERESIS; MALE; MIDDLE AGED; MYALGIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; RISK ASSESSMENT; SKIN REDNESS; T LYMPHOCYTE; UPREGULATION; VACCINATION; YOUNG ADULT; ADVERSE EFFECTS; ALLOTRANSPLANTATION; BELGIUM; BIOSYNTHESIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; GENETIC TRANSFECTION; GENETICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNIZATION; IMMUNOLOGY; INTRADERMAL DRUG ADMINISTRATION; METABOLISM; NORMAL HUMAN; TIME; TRANSPLANTATION; TREATMENT OUTCOME; VIROLOGY;

ADULT; BELGIUM; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; CYTOMEGALOVIRUS VACCINES; DENDRITIC CELLS; FEASIBILITY STUDIES; FEMALE; HEALTHY VOLUNTEERS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNIZATION SCHEDULE; INJECTIONS, INTRADERMAL; MALE; MIDDLE AGED; PHOSPHOPROTEINS; RNA, MESSENGER; RNA, VIRAL; T-LYMPHOCYTES; TIME FACTORS; TRANSFECTION; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; VACCINATION; VIRAL MATRIX PROTEINS; YOUNG ADULT;

EID: 84920265123     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000000272     Document Type: Article

References (40)

1. Cainelli F, Vento S. Infections and solid organ transplant rejection: a causeand-effect relationship? Lancet Infect Dis 2002;2:539.
2. Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med 2007;357:2601.
3. Ljungman P. CMV infections after hematopoietic stem cell transplantation. Bone Marrow Transplant 2008;42(Suppl 1):S70.
4. Rowshani AT, Bemelman FJ, van Leeuwen EM, et al. Clinical and immunologic aspects of cytomegalovirus infection in solid organ transplant recipients. Transplantation 2005;79:381.
5. Smits EL, Berneman ZN. Viral infections following allogeneic stem cell transplantation: how to cure the cure? Leuk Lymphoma 2010;51:965.
6. Fishman JA, Rubin RH. Infection in organ-transplant recipients. N Engl J Med 1998;338:1741.
7. Beam E, Razonable RR. Cytomegalovirus in solid organ transplantation: epidemiology, prevention, and treatment. Curr Infect Dis Rep 2012;14:633.
8. Manuel O, Pang XL, Humar A, et al. An assessment of donor-to-recipient transmission patterns of human cytomegalovirus by analysis of viral genomic variants. J Infect Dis 2009;199:1621.
9. Wills MR, Carmichael AJ, Mynard K, et al. The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL. J Virol 1996;70:7569.
10. McLaughlin-Taylor E, Pande H, Forman SJ, et al. Identification of the major late human cytomegalovirus matrix protein pp65 as a target antigen for CD8+ virus-specific cytotoxic T lymphocytes. J Med Virol 1994;43:103.
11. Plotkin SA, Higgins R, Kurtz JB, et al. Multicenter trial of Towne strain attenuated virus vaccine in seronegative renal transplant recipients. Transplantation 1994;58:1176.
12. Boeckh M, Leisenring W, Riddell SR, et al. Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood 2003;101:407.
13. Lilleri D, GernaG, Fornara C, et al. Prospective simultaneous quantification of human cytomegalovirus-specific CD4+ and CD8+ T-cell reconstitution in young recipients of allogeneic hematopoietic stem cell transplants. Blood 2006;108:1406.
14. Pass RF, Zhang C, Evans A, et al. Vaccine prevention of maternal cytomegalovirus infection. N Engl JMed 2009;360:1191.
15. Griffiths PD, Stanton A, McCarrell E, et al. Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial. Lancet 2011;377:1256.
16. Sylwester AW, Mitchell BL, Edgar JB, et al. Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects. J Exp Med 2005;202:673.
17. Walter EA, Greenberg PD, Gilbert MJ, et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 1995;333:1038.
18. Einsele H, Roosnek E, Rufer N, et al. Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood 2002;99:3916.
19. Van den BoschGA, Ponsaerts P, Vanham G, et al. Cellular immunotherapy for cytomegalovirus and HIV-1 infection. J Immunother 2006;29:107.
20. Bernstein DI, Reap EA, Katen K, et al. Randomized, double-blind, Phase 1 trial of an alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteers. Vaccine 2009;28:484.
21. Kharfan-Dabaja MA, Boeckh M, Wilck MB, et al. A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis 2012;12:290.
22. Peggs KS, Verfuerth S, Pizzey A, et al. Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines. Lancet 2003;362:1375.
23. Feuchtinger T, Opherk K, Bicanic O, et al. Dendritic cell vaccination in an allogeneic stem cell recipient receiving a transplant from a human cytomegalovirus (HCMV)-seronegative donor: induction of a HCMVspecific T(helper) cell response. Cytotherapy 2010;12:945.
24. Deeg HJ, Henslee-Downey PJ. Management of acute graft-versus-host disease. Bone Marrow Transplant 1990;6:1.
25. Grigoleit GU, Kapp M, Hebart H, et al. Dendritic cell vaccination in allogeneic stem cell recipients: induction of human cytomegalovirus (HCMV)-specific cytotoxic T lymphocyte responses even in patients receiving a transplant from an HCMV-seronegative donor. J Infect Dis 2007;196:699.
26. Celli S, Day M, Muller AJ, et al. How many dendritic cells are required to initiate a T-cell response? Blood 2012;120:3945.
27. Aarntzen EH, Srinivas M, Bonetto F, et al. Targeting of 111In-Labeled Dendritic Cell Human Vaccines Improved by Reducing Number of Cells. Clin Cancer Res 2013;19:1525.
28. Boeckh M, Bowden RA, Goodrich JM, et al. Cytomegalovirus antigen detection in peripheral blood leukocytes after allogeneic marrow transplantation. Blood 1992;80:1358.
29. Nichols WG, Corey L, Gooley T, et al. Rising pp65 antigenemia during preemptive anticytomegalovirus therapy after allogeneic hematopoietic stem cell transplantation: risk factors, correlation with DNA load, and outcomes. Blood 2001;97:867.
30. Trenschel R, Ross S, Husing J, et al. Reduced risk of persisting cytomegalovirus pp65 antigenemia and cytomegalovirus interstitial pneumonia following allogeneic PBSCT. Bone Marrow Transplant 2000;25:665.
31. Ljungman P, Brand R, Einsele H, et al. Donor CMV serologic status and outcome of CMV-seropositive recipients after unrelated donor stem cell transplantation: an EBMT megafile analysis. Blood 2003;102:4255.
32. Ljungman P, Hakki M, Boeckh M. Cytomegalovirus in hematopoietic stem cell transplant recipients. Infect Dis Clin North Am 2010;24:319.
33. Li CR, Greenberg PD, Gilbert MJ, et al. Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis. Blood 1994;83:1971.
34. Reusser P, Cathomas G, Attenhofer R, et al. Cytomegalovirus (CMV)-specific T cell immunity after renal transplantation mediates protection from CMV disease by limiting the systemic virus load. J Infect Dis 1999;180:247.
35. Riddell SR, Watanabe KS, Goodrich JM, et al. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of Tcell clones. Science 1992;257:238.
36. Van Driessche A, Van de Velde AL, Nijs G, et al. Clinical-grade manufacturing of autologous mature mRNA-electroporated dendritic cells and safety testing in acute myeloid leukemia patients in a phase I doseescalation clinical trial. Cytotherapy 2009;11:653.
37. Van Tendeloo VF, Van de Velde A, Van Driessche A, et al. Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination. Proc Natl Acad Sci U S A 2010;107:13824.
38. Van Gulck E, Vlieghe E, Vekemans M, et al. mRNA-based dendritic cell vaccination induces potent antiviral T-cell responses in HIV-1-infected patients. AIDS 2012;26:F1.
39. Van Camp K, Cools N, Stein B, et al. Efficient mRNA electroporation of peripheral blood mononuclear cells to detect memory T cell responses for immunomonitoring purposes. J Immunol Methods 2010;354:1.
40. Moodie Z, Price L, Gouttefangeas C, et al. Response definition criteria for ELISPOT assays revisited. Cancer Immunol Immunother 2010;59:1489.